By abrogating both MDM2/MDM4 and XIAP-mediated survival mechanisms, MMRi36 bypassed p53 and mitochondria events to induce p53-independent apoptosis, a desirable endpoint for relapsed lymphoma patients that no longer respond to current chemotherapies. Here, TP53 is linked to lymphoma.